Semaglutide and Ozempic for weight loss: the facts

You've read about Ozempic online, here's what's actually happening

Picture the scenario: you come across social media posts, news articles, or a friend's story about Ozempic transforming someone's weight. You search 'semaglutide Ozempic for weight loss' and land in a maze of conflicting information. Some sites discuss it freely; others warn you off. The confusion is real, and it's worth unpicking.

Ozempic contains semaglutide at doses of 0.5mg, 1mg, and 2mg. It was developed and licensed for blood-sugar control in adults with type 2 diabetes. Doctors noticed weight loss as a consistent side effect. That observation eventually led Novo Nordisk to run a separate clinical programme (the STEP trials) at a higher dose (2.4mg) specifically for weight management. The result was Wegovy, a distinct product with its own MHRA licence. The two products share a molecule, nothing else about their regulatory status in the UK.

Prescribing Ozempic for weight loss in a person without diabetes is an off-label use. It happens in some clinical contexts, but it is not routine, not the standard of care, and not what most regulated UK weight-loss services offer. Our guide on Ozempic and semaglutide covers the diabetes versus weight-loss distinction in full detail if you want the complete picture.

What semaglutide actually does, and why the dose matters for weight loss

Semaglutide is a GLP-1 receptor agonist. GLP-1 is a gut hormone released after eating; it signals fullness to the brain, slows stomach emptying, and plays a role in insulin secretion. Semaglutide mimics that signal continuously, which is why people on it tend to feel satisfied sooner and eat less without consciously counting every calorie.

The dose relationship is important. Ozempic tops out at 2mg weekly. Wegovy's maintenance dose is 2.4mg, which sounds like a modest step up, but in the STEP 1 trial, published in the New England Journal of Medicine, that dose produced an average 15% body-weight reduction over 68 weeks in adults without diabetes. Participants who stayed fully adherent saw larger reductions. The licensed dose exists because the clinical programme was built around it.

Wegovy also now comes in a 7.2mg maintenance dose, approved by the MHRA in January 2026. Trial data at that dose showed average weight loss of around 20.7% over 72 weeks, approaching results seen with tirzepatide. If you are weighing up which medicine suits your situation, this comparison of Wegovy and Ozempic walks through the evidence without the marketing.

Which medicines are actually licensed for weight loss in the UK right now

Two injectable medicines hold UK licences specifically for weight management in adults: Wegovy (semaglutide 2.4mg, up to 7.2mg) and Mounjaro (tirzepatide), a dual GIP and GLP-1 receptor agonist made by Eli Lilly. NICE appraised both; guidance for tirzepatide is at TA1026 and for semaglutide at TA875.

A third option appeared in June 2026: Wegovy tablets, the first oral GLP-1 medicine licensed in the UK for weight management, approved by the MHRA on 11 June 2026. The tablet formulation uses the same semaglutide molecule with an absorption enhancer; it reaches a 25mg daily maintenance dose and is taken on an empty stomach each morning. Clinical trial data (OASIS 4, 64 weeks) showed an average weight reduction of around 13.6% versus placebo regardless of adherence, and approximately 17% among participants who stayed fully adherent throughout. That figure matters for anyone who has wondered whether a pill might work as well as a pen.

None of this means Ozempic is ineffective for weight loss at a biological level. It means that for UK patients seeking a clinically supervised, properly licensed treatment, Wegovy and Mounjaro are the appropriate options. Our overview of weight-loss medicines and the Ozempic-Wegovy relationship sets out the full context, including what the NHS covers and what private services offer.

Getting started: what private access through a regulated UK pharmacy actually involves

If you have been on Ozempic for diabetes and are wondering whether you could switch to a weight-loss medicine, or if you are new to GLP-1 medicines entirely, the route through a private regulated pharmacy is the same: a clinical consultation, identity and weight verification, a GPhC-registered prescriber reviewing your answers (a real clinician, not software), and, once approved, treatment dispatched the same working day for next-day delivery.

Because these are prescription-only medicines, no legitimate UK service can skip the assessment. That check exists to catch contraindications (pancreatitis history, certain thyroid conditions, interactions with other medicines, suitability during or after pregnancy) not to create a barrier for its own sake. For anyone wondering about the cost side of things, our semaglutide weight-loss treatment page covers what's included in a private prescription and what to compare when you see headline prices elsewhere.

One practical detail: ordering works best when you plan ahead. The 12pm Monday-to-Friday cut-off for same-day dispatch catches a lot of people out around bank holidays, so if you are starting treatment near a long weekend, check the dispatch calendar. It is a small thing, but running low mid-titration is more disruptive than it sounds.

If you would like to explore whether Wegovy or Mounjaro might suit you, checking your eligibility with our prescribers is the natural next step, and if you are based in the north-west, our Wegovy Manchester page has details on how local patients can get started. There is no obligation at that point, and the consultation is free.